Ariz. Admin. Code § R9-6-344 - Haemophilus influenzae: Invasive Disease
A. Case control measures:
1. A diagnosing health care provider or an
administrator of a health care institution, either personally or through a
representative, shall isolate and institute droplet precautions for a
Haemophilus influenzae meningitis or epiglottitis case or
suspect case for 24 hours after the initiation of treatment.
2. A local health agency shall:
a.b.
Conduct an epidemiologic investigation of each reported Haemophilus
influenzae invasive disease case or suspect case; and
b.c. For
each Haemophilus influenzae invasive disease case, submit to
the Department, as specified in Table 2.4, the information required under
R9-6-206(D).
a. Upon receiving a report of a
Haemophilus influenzae invasive disease case or suspect case,
notify the Department within one working day after receiving the report and
provide to the Department the information contained in the report;
B. Contact control measures: A local health
agency shall evaluate the level of risk of transmission from each contact's
exposure to a Haemophilus influenzae invasive disease case
and, if indicated, shall provide or arrange for each contact to receive
immunization or treatment.
Notes
State regulations are updated quarterly; we currently have two versions available. Below is a comparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare.
A. Case control measures:
1. A local health agency shall:
a. Evaluate a health care provider identified as the source of hepatitis B virus transmission in the work place and, if indicated, ensure reassignment of the health care provider to a position where the occupational risk of transmission is eliminated;
b. Conduct an epidemiologic investigation of each reported case or suspect case of hepatitis B or hepatitis B co-infected with hepatitis D; and
c. For each acute case of hepatitis B or hepatitis B co-infected with hepatitis D or case of perinatal hepatitis B, submit to the Department, as specified in Table 2.4, the information required under R9-6-206(D).
2. The operator of a blood bank , blood center , or plasma center shall notify a donor of a test result with significant evidence suggestive of hepatitis B, as required under A.R.S. § 32-1483 and 21 CFR 630.6.
B. Contact control measures: A local health agency shall:
1. Refer each non-immune hepatitis B contact to a health care provider for prophylaxis and initiation of the hepatitis B vaccine series, and
2. Provide health education related to the progression of hepatitis B disease and the prevention of transmission of hepatitis B infection to each non-immune hepatitis B contact.